Henk M W Verheul

List of Publications by Year
in descending order

295	11,263	36303	36028
papers	citations	51 h-index	97 g-index

301	301	301	17220
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment. Clinical Cancer Research, 2022, 28, 1402-1411.	7.0	24
2	Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform. Lancet Oncology, The, 2022, 23, 198-201.	10.7	14
3	Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2022, 28, 1595-1602.	7.0	12
4	Development of a miRNAâ€based classifier for detection of colorectal cancer molecular subtypes. Molecular Oncology, 2022, 16, 2693-2709.	4.6	6
5	In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival. Annals of Surgical Oncology, 2022, 29, 5256-5262.	1.5	1
6	ASO Visual Abstract: In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is Not a Prognostic Marker for Survival. Annals of Surgical Oncology, 2022, , 1.	1.5	0
7	Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treatment Reviews, 2022, 109, 102433.	7.7	15
8	Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial. Oncologist, 2021, 26, e173-e181.	3.7	7
9	Predicting outcome in older patients with cancer: Comprehensive geriatric assessment and clinical judgment. Journal of Geriatric Oncology, 2021, 12, 49-56.	1.0	3
10	Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era. British Journal of Cancer, 2021, 124, 399-406.	6.4	19
11	A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. British Journal of Cancer, 2021, 124, 728-735.	6.4	64
12	Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials. Supportive Care in Cancer, 2021, 29, 3783-3792.	2.2	2
13	A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26â€“104/RFASE in Patients with Advanced Solid Malignancies. Oncologist, 2021, 26, e218-e229.	3.7	4
14	Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies. Molecular Oncology, 2021, 15, 901-914.	4.6	7
15	10-year outcome of a randomized trial comparing neoadjuvant chemoradiotherapy and surgery with surgery alone for esophageal cancer (CROSS trial). European Journal of Surgical Oncology, 2021, 47, e31.	1.0	1
16	Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients. Clinical Proteomics, 2021, 18, 8.	2.1	2
17	Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers, 2021, 13, 711.	3.7	18
18	Conversion of a colorectal cancer guideline into clinical decision trees with assessment of validity. International Journal for Quality in Health Care, 2021, 33, .	1.8	11

#	Article	IF	Citations
19	A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype. Clinical and Translational Science, 2021, 14, 954-963.	3.1	5
20	Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology. Cancers, 2021, 13, 2304.	3.7	2
21	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 161.	8.6	16
22	Prediction of response to sunitinib in patients with advanced renal cell carcinoma (RCC) using mass spectrometry-based (phospho) proteomics.. Journal of Clinical Oncology, 2021, 39, e16556-e16556.	1.6	0
23	Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases. JAMA Surgery, 2021, 156, 710-720.	4.3	34
24	Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study. Physiological Reports, 2021, 9, e14919.	1.7	13
25	High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review. Cancer Treatment Reviews, 2021, 97, 102171.	7.7	8
26	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of Clinical Oncology, 2021, 39, 1995-2004.	1.6	291
27	Effects of Cancer Presence and Therapy on the Platelet Proteome. International Journal of Molecular Sciences, 2021, 22, 8236.	4.1	8
28	Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. Nature Medicine, 2021, 27, 1553-1563.	30.7	41
29	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. Clinical Cancer Research, 2021, 27, 6106-6114.	7.0	9
30	The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy. Cancer Treatment and Research Communications, 2021, 27, 100371.	1.7	4
31	Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment. JAMA Surgery, 2021, 156, 1093.	4.3	34
32	Diagnostic Performance of [18F]FDG PET in Staging Grade 1â€“2, Estrogen Receptor Positive Breast Cancer. Diagnostics, 2021, 11, 1954.	2.6	10
33	Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. Cancers, 2021, 13, 5446.	3.7	12
34	Clinical judgment of the need for professional mental health care in patients with cancer: a qualitative study among oncologists and nurses. Journal of Cancer Survivorship, 2021, , 1.	2.9	1
35	Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. Oncologist, 2020, 25, e570-e577.	3.7	10
36	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1875.	3.7	19

#	Article	IF	Citations
37	Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. Cancers, 2020, 12, 3322.	3.7	10
38	A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer. Cancer Medicine, 2020, 9, 7558-7571.	2.8	9
39	11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy. Journal of Nuclear Medicine, 2020, 62, jnumed.120.251611.	5.0	0
40	Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines. Molecular and Cellular Proteomics, 2020, 19, 884-899.	3.8	29
41	Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer. Oncologist, 2020, 25, e1195-e1201.	3.7	7
42	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. Scientific Reports, 2020, 10, 9778.	3.3	5
43	The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review. Cancers, 2020, 12, 586.	3.7	48
44	Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study. Cancer Chemotherapy and Pharmacology, 2020, 86, 141-150.	2.3	3
45	Muscle contractile properties of cancer patients receiving chemotherapy: Assessment of feasibility and exercise effects. Scandinavian Journal of Medicine and Science in Sports, 2020, 30, 1918-1929.	2.9	8
46	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nature Communications, 2020, 11, 525.	12.8	158
47	CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer. Cells, 2020, 9, 124.	4.1	5
48	Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas: Propensity Scoreâ€“Matched Analysis of Centers in the Netherlands and Belgium. Clinical Colorectal Cancer, 2020, 19, e87-e99.	2.3	6
49	Clinical assessment of emotions in patients with cancer: Diagnostic accuracy compared with two reference standards. Psycho-Oncology, 2020, 29, 775-780.	2.3	4
50	Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. Cancers, 2020, 12, 330.	3.7	11
51	Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. EJNMMI Research, 2020, 10, 40.	2.5	13
52	Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa151.	0.7	1
53	Clinical management of emotions in patients with cancer: introducing the approach â€œemotional support and case findingâ€• Translational Behavioral Medicine, 2020, 10, 1399-1405.	2.4	8
54	634â€…Production and testing of a novel bispecific nanobody construct targeting NK cells and EGFR expressing malignancies. , 2020, , .		0

#	Article	IF	Citations
55	Constitutively active GSK3Î² as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression. OncoImmunology, 2019, 8, e1631119.	4.6	8
56	<scp>RAS</scp> and <scp>BRAF</scp> mutations in cellâ€free <scp>DNA</scp> are predictive for outcome of cetuximab monotherapy in patients with tissueâ€tested <scp>RAS</scp> wildâ€type advanced colorectal cancer. Molecular Oncology, 2019, 13, 2361-2374.	4.6	32
57	Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin. BMC Cancer, 2019, 19, 1066.	2.6	18
58	Proteomic Analysis of miR-195 and miR-497 Replacement Reveals Potential Candidates that Increase Sensitivity to Oxaliplatin in MSI/P53wt Colorectal Cancer Cells. Cells, 2019, 8, 1111.	4.1	25
59	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1931-1939.	6.4	53
60	Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2019, 37, 411-418.	1.6	16
61	<scp>INKA</scp> , an integrative data analysis pipeline for phosphoproteomic inference of active kinases. Molecular Systems Biology, 2019, 15, e8250.	7.2	53
62	Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Annals of Oncology, 2019, 30, 663-665.	1.2	21
63	Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer, 2019, 19, 390.	2.6	83
64	Accuracy of the Delirium Observational Screening Scale (DOS) as a screening tool for delirium in patients with advanced cancer. BMC Cancer, 2019, 19, 160.	2.6	20
65	Predictors for use of psychosocial services in patients with metastatic colorectal cancer receiving first line systemic treatment. BMC Cancer, 2019, 19, 115.	2.6	12
66	Optimal treatment of opioid induced constipation in daily clinical practice â€“ an observational study. BMC Palliative Care, 2019, 18, 31.	1.8	10
67	Immuno-PET Imaging to Assess Target Engagement: Experience from ⁸⁹Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. Journal of Nuclear Medicine, 2019, 60, 902-909.	5.0	50
68	O200 10-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL COMPARING NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VERSUS SURGERY ALONE FOR OESOPHAGEAL OR JUNCTIONAL CANCER (CROSS). Ecological Management and Restoration, 2019, 32, .	0.4	0
69	How Does a Supervised Exercise Program Improve Quality of Life in Patients with Cancer? A Concept Mapping Study Examining Patients' Perspectives. Oncologist, 2019, 24, e374-e383.	3.7	10
70	Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone. Clinical Genitourinary Cancer, 2019, 17, e281-e292.	1.9	9
71	First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using ⁸⁹Zr-Df-CPC634 PET/CT.. Journal of Clinical Oncology, 2019, 37, 3093-3093.	1.6	3
72	CD276-positive circulating endothelial cells in advanced colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 572-572.	1.6	2

#	Article	IF	Citations
73	Screening and Stepped Care Targeting Psychological Distress in Patients With Metastatic Colorectal Cancer: The TES Cluster Randomized Trial. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 911-920.	4.9	16
74	Comparison of phosphoproteomic profiles in left- and right-sided colorectal cancers.. Journal of Clinical Oncology, 2019, 37, 582-582.	1.6	0
75	Abstract C079: Effect of food on the pharmacokinetics of high dose intermittent sunitinib in patients with advanced solid tumors. , 2019, , .		0
76	Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 616-628.	10.7	397
77	A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. European Journal of Cancer, 2018, 90, 1-9.	2.8	20
78	Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab. Angiogenesis, 2018, 21, 325-334.	7.2	20
79	A safety and immunogenicity study of immunization with hVEGF 26-104 /RFASE in cynomolgus monkeys. Vaccine, 2018, 36, 2025-2032.	3.8	6
80	FDG PET and FES PET Predict PFS on Endocrine Therapyâ€"Letter. Clinical Cancer Research, 2018, 24, 248-248.	7.0	1
81	Evaluation of several methodological challenges in circulating miRNA qPCR studies in patients with head and neck cancer. Experimental and Molecular Medicine, 2018, 50, e454-e454.	7.7	59
82	The effects of systemic treatment with aminobisphosphonates and statins on circulating Vî³9Vî´2-T cells in patients with advanced cancer. Immunobiology, 2018, 223, 171-177.	1.9	4
83	A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vî³9Vî´2-T cells. OncoImmunology, 2018, 7, e1375641.	4.6	61
84	Higher Muscle Strength Is Associated with Prolonged Survival in Older Patients with Advanced Cancer. Oncologist, 2018, 23, 580-585.	3.7	61
85	Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e1-e9.	1.9	11
86	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. Journal of Clinical Oncology, 2018, 36, 2052-2060.	1.6	26
87	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. Journal of Clinical Oncology, 2018, 36, 268-275.	1.6	91
88	Feasibility, validity and reliability of objective smartphone measurements of physical activity and fitness in patients with cancer. BMC Cancer, 2018, 18, 1052.	2.6	31
89	Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-NaÃ¯ve Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1481-1488.	4.9	13
90	Cancer Cachexia: Identification by Clinical Assessment versus International Consensus Criteria in Patients with Metastatic Colorectal Cancer. Nutrition and Cancer, 2018, 70, 1322-1329.	2.0	13

#	Article	IF	Citations
91	The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy. Cancer Management and Research, 2018, Volume 10, 3015-3021.	1.9	10
92	The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer. European Journal of Cancer, 2018, 103, 160-164.	2.8	8
93	Rscreenorm: normalization of CRISPR and siRNA screen data for more reproducible hit selection. BMC Bioinformatics, 2018, 19, 301.	2.6	12
94	Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. PLoS ONE, 2018, 13, e0201809.	2.5	20
95	Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study. Oncologist, 2018, 23, 1135.	3.7	2
96	Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2404-2412.	6.4	21
97	Taste Alterations During Treatment With Protein Kinase Inhibitors: A Pilot Study. Journal of Pain and Symptom Management, 2018, 56, e1-e4.	1.2	1
98	Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody. EJNMMI Research, 2018, 8, 6.	2.5	11
99	Colorectal liver metastases: surgery versus thermal ablation (COLLISION) â€“ a phase III single-blind prospective randomized controlled trial. BMC Cancer, 2018, 18, 821.	2.6	154
100	Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC. Annals of Surgical Oncology, 2018, 25, 2347-2356.	1.5	18
101	Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) â€" Results of the Dutch HOVON 123 Study. Blood, 2018, 132, 1889-1889.	1.4	11
102	Screening and stepped care targeting psychological distress in patients with metastatic colorectal cancer: The TES cluster randomized trial.. Journal of Clinical Oncology, 2018, 36, 3560-3560.	1.6	3
103	Circulating tumor DNA dynamics in resectable gastric cancer.. Journal of Clinical Oncology, 2018, 36, 4069-4069.	1.6	2
104	Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: Results of a phase I exposure escalation study.. Journal of Clinical Oncology, 2018, 36, e14560-e14560.	1.6	0
105	A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso.. Journal of Clinical Oncology, 2018, 36, e15584-e15584.	1.6	1
106	Abstract 2579: Loss of chromosome 18q11.2-18q12.1 is predictive for progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. , 2018, , .		0
107	Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity. Angiogenesis, 2017, 20, 287-289.	7.2	9
108	Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. Clinical Genitourinary Cancer, 2017, 15, e773-e782.	1.9	33

#	Article	IF	Citations
109	Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection. Journal of Proteomics, 2017, 162, 99-107.	2.4	31
110	A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1319-1327.	6.4	15
111	The influence of different muscle mass measurements on the diagnosis of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 615-622.	7.3	62
112	Muscle mass as a target to reduce fatigue in patients with advanced cancer. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 623-629.	7.3	72
113	A Phase 1 Trial of Cabazitaxel Combined With 188Reâ€“Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment. Clinical Nuclear Medicine, 2017, 42, 415-420.	1.3	2
114	The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis, 2017, 20, 217-232.	7.2	26
115	Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. Scientific Reports, 2017, 7, 44686.	3.3	66
116	Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody. Journal of Immunology, 2017, 198, 308-317.	0.8	9
117	Insight in taste alterations during treatment with protein kinase inhibitors. European Journal of Cancer, 2017, 86, 125-134.	2.8	20
118	Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. Journal of Nuclear Medicine, 2017, 58, 1906-1912.	5.0	48
119	Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. Journal of Neuro-Oncology, 2017, 135, 183-192.	2.9	138
120	Identification of patients with cancer with a high risk to develop delirium. Cancer Medicine, 2017, 6, 1861-1870.	2.8	12
121	Patient-Reported Symptom Monitoring During Chemotherapy. JAMA - Journal of the American Medical Association, 2017, 318, 1935.	7.4	0
122	Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis. Cancer and Metastasis Reviews, 2017, 36, 395-406.	5.9	25
123	Plasma Ghrelin Levels Are Associated with Anorexia but Not Cachexia in Patients with NSCLC. Frontiers in Physiology, 2017, 8, 119.	2.8	14
124	In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. Frontiers in Immunology, 2017, 8, 87.	4.8	43
125	The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Frontiers in Immunology, 2017, 8, 631.	4.8	154
126	Identification of novel therapeutic targets in glioblastoma with functional genomic mRNA profiling.. Journal of Clinical Oncology, 2017, 35, 2018-2018.	1.6	5

#	Article	IF	Citations
127	A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors.. Journal of Clinical Oncology, 2017, 35, 2556-2556.	1.6	6
128	A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, 2591-2591.	1.6	1
129	The impact of cumulative toxicity on physical quality of life in patients with metastatic colorectal cancer receiving first line chemotherapy.. Journal of Clinical Oncology, 2017, 35, 3564-3564.	1.6	1
130	Pharmacokinetics of cetuximab and tumor uptake of ⁸⁹Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15117-e15117.	1.6	2
131	A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.. Journal of Clinical Oncology, 2017, 35, 166-166.	1.6	2
132	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget, 2017, 8, 63140-63154.	1.8	19
133	Safety and feasibility of adding tumor debulking to palliative chemotherapy in multi-organ metastatic colorectal cancer: The ORCHESTRA trial.. Journal of Clinical Oncology, 2017, 35, 3553-3553.	1.6	0
134	Change in metabolic tumor activity on ¹⁸F-FDG PET after a single dose of cetuximab to predict for treatment benefit, PFS, and OS in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 11519-11519.	1.6	0
135	Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: A phase I exposure escalation study.. Journal of Clinical Oncology, 2017, 35, TPS2620-TPS2620.	1.6	0
136	The Drug Rediscovery Protocol (DRUP).. Journal of Clinical Oncology, 2017, 35, 2547-2547.	1.6	0
137	Abstract 2208: Peptide-mediated 'miniprep' isolation of extracellular vesicles is suitable for high-throughput proteomics; method evaluation and application in colon cancer. , 2017, , .		0
138	Objective smartphone measurements of physical activity and fitness in patients with cancer.. Journal of Clinical Oncology, 2017, 35, 132-132.	1.6	0
139	Efficacy and side effect profile of olanzapine versus haloperidol for symptoms of delirium in hospitalized patients with advanced cancer: A multicenter, investigator-blinded, randomized, controlled trial (RCT).. Journal of Clinical Oncology, 2017, 35, 231-231.	1.6	1
140	Clinical assessment of emotions in patients with cancer: Diagnostic accuracy compared to two reference standards.. Journal of Clinical Oncology, 2017, 35, 24-24.	1.6	12
141	Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers, 2016, 8, 81.	3.7	61
142	Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth. Journal of Experimental and Clinical Cancer Research, 2016, 35, 138.	8.6	17
143	Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. PLoS ONE, 2016, 11, e0157830.	2.5	69
144	Response and toxicity prediction by MALDIâ€TOFâ€MS serum peptide profiling in patients with nonâ€small cell lung cancer. Proteomics - Clinical Applications, 2016, 10, 743-749.	1.6	4

#	Article	IF	Citations
145	Highly specific and potently activating Vî³9Vî´2-T cell specific nanobodies for diagnostic and therapeutic applications. Clinical Immunology, 2016, 169, 128-138.	3.2	29
146	Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies. Clinical Therapeutics, 2016, 38, 2286-2299.	2.5	42
147	Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer. Experimental and Molecular Medicine, 2016, 48, e279-e279.	7.7	22
148	Reply to L.E. Daly et al. Journal of Clinical Oncology, 2016, 34, 3817-3817.	1.6	3
149	Sunitinib activates Axl signaling in renal cell cancer. International Journal of Cancer, 2016, 138, 3002-3010.	5.1	32
150	A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer. British Journal of Cancer, 2016, 115, 940-948.	6.4	4
151	Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. Journal of Neuro-Oncology, 2016, 129, 221-230.	2.9	13
152	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. Digestion, 2016, 94, 129-137.	2.3	10
153	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. OncoImmunology, 2016, 5, e1105431.	4.6	11
154	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibodyâ€“Drug Conjugate Treatment. Clinical Cancer Research, 2016, 22, 1642-1652.	7.0	74
155	Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2016, 34, 1339-1344.	1.6	279
156	Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. European Urology, 2016, 70, 416-426.	1.9	51
157	Abstract CT017: A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients. , 2016, , .		2
158	Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, 11553-11553.	1.6	2
159	Pharmacokinetic (PK) effects and safety of olaparib in combination with tamoxifen, anastrozole, or letrozole: Phase I study.. Journal of Clinical Oncology, 2016, 34, 2562-2562.	1.6	2
160	A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.. Journal of Clinical Oncology, 2016, 34, 5081-5081.	1.6	1
161	A phase I trial of cabazitaxel Â± rhenium-188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment.. Journal of Clinical Oncology, 2016, 34, e16508-e16508.	1.6	1
162	The ORCHESTRA trial: A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, TPS788-TPS788.	1.6	2

#	Article	IF	Citations
163	Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2016, 11, e0155178.	2.5	4
164	First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget, 2016, 7, 80046-80058.	1.8	90
165	Mass spectrometry-based phosphoproteomics of tumor needle biopsies from patients (pts) with advanced solid tumors during treatment with protein kinase inhibitors.. Journal of Clinical Oncology, 2016, 34, 11609-11609.	1.6	0
166	Umbilical cord blood stem cell derived NK cells as universal treatment for metastatic colorectal cancer using EGFR independent killing mechanisms.. Journal of Clinical Oncology, 2016, 34, e14525-e14525.	1.6	0
167	Allogeneic NK cells generated from cord blood as universal treatment for cervical cancer enabled by HLA independent killing mechanisms.. Journal of Clinical Oncology, 2016, 34, e14526-e14526.	1.6	0
168	Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer (AEGC).. Journal of Clinical Oncology, 2016, 34, e15555-e15555.	1.6	0
169	Does treatment-related toxicity affect quality of life in patients with metastatic colorectal cancer? A systematic review.. Journal of Clinical Oncology, 2016, 34, e18106-e18106.	1.6	0
170	Abstract 3885: Peptide-mediated â€˜miniprepâ€™ isolation of extracellular vesicles for high-throughput proteomics; method evaluation and application in colon cancer. , 2016, , .		0
171	Abstract 880: Mapping the metastatic colorectal cancer phospho-proteome for predicting response to cetuximab. , 2016, , .		0
172	Abstract 4928: MiR expression profiles can predict response to systemic treatment in patients with advanced colorectal cancer. , 2016, , .		0
173	Dried blood spot analysis for therapeutic drug monitoring of pazopanib. Journal of Clinical Pharmacology, 2015, 55, 1344-1350.	2.0	26
174	Screening and treatment of psychological distress in patients with metastatic colorectal cancer: study protocol of the TES trial. BMC Cancer, 2015, 15, 302.	2.6	18
175	Platelets: an unexploited data source in biomarker research. Lancet Haematology,the, 2015, 2, e512-e513.	4.6	19
176	What is the benefit of treatment with multiple lines of chemotherapy for patients with metastatic breast cancer? A retrospective cohort study. Cancer Epidemiology, 2015, 39, 848-853.	1.9	8
177	Vaccination approach to anti-angiogenic treatment of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 155-171.	7.4	22
178	Bevacizumab in Combination With Radiotherapy and Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme. Oncologist, 2015, 20, 107-108.	3.7	18
179	New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?. Clinical Genitourinary Cancer, 2015, 13, 271-279.	1.9	34
180	Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cellular Oncology (Dordrecht), 2015, 38, 119-129.	4.4	46

#	Article	IF	Citations
181	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncology, The, 2015, 16, 1090-1098.	10.7	1,861
182	Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. Advances in Therapy, 2015, 32, 510-522.	2.9	39
183	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. Clinical Immunology, 2015, 158, 92-99.	3.2	2
184	Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines. Journal of Proteomics, 2015, 127, 247-258.	2.4	45
185	Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics. Journal of Proteomics, 2015, 127, 259-263.	2.4	43
186	The effect of individualized NUTritional counseling on muscle mass and treatment outcome in patients with metastatic COLOrectal cancer undergoing chemotherapy: a randomized controlled trial protocol. BMC Cancer, 2015, 15, 98.	2.6	14
187	Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial. BMC Cancer, 2015, 15, 180.	2.6	57
188	Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 4569-4575.	7.0	12
189	CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clinical Cancer Research, 2015, 21, 2753-2762.	7.0	42
190	Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials. Supportive Care in Cancer, 2015, 23, 2499-2506.	2.2	9
191	Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care. Cellular Oncology (Dordrecht), 2015, 38, 49-64.	4.4	23
192	Abstract 2496: Preclinical testing of a novel anti-angiogenic vaccine targeting human VEGF. , 2015, , .		2
193	Abstract OT3-2-01: IMPACT: IMaging PAtients for Cancer drug selecTion â€“ Metastatic breast cancer (MBC). , 2015, , .		4
194	Effect of itraconazole and rifampin on the pharmacokinetics of olaparib tablet formulation in patients with advanced solid tumours: Phase I open-label studies.. Journal of Clinical Oncology, 2015, 33, 2565-2565.	1.6	1
195	CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.. Journal of Clinical Oncology, 2015, 33, 3016-3016.	1.6	12
196	A novel combinatorial therapy using cytolytic NK cells and anti-EGFR moAb to improve the treatment of EGFR expressing solid tumors.. Journal of Clinical Oncology, 2015, 33, e14017-e14017.	1.6	1
197	Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, TPS3097-TPS3097.	1.6	3
198	The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer. Journal of Kidney Cancer and VHL, 2015, 2, 195-203.	1.0	18

#	Article	IF	Citations
199	89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget, 2015, 6, 30384-30393.	1.8	106
200	A phase I study of investigational agent SGI-110 combined with irinotecan in previously treated metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2015, 33, TPS797-TPS797.	1.6	1
201	Abstract A18: Genome-wide methylation profiling to identify potential epigenetic biomarkers associated with response to sunitinib in metastatic renal cell cancer patients (pts). , 2015, , .		0
202	Allowance of tumor-educated platelets for multiclass liquid biopsy-based diagnosis of cancer.. Journal of Clinical Oncology, 2015, 33, 11058-11058.	1.6	0
203	Comparison of deep sequencing miRNA expression analysis in primary colorectal cancer and paired metastases.. Journal of Clinical Oncology, 2015, 33, e14682-e14682.	1.6	0
204	A phase 1 study of weekly high dose sunitinib in patients with advanced solid tumors: Early signs of activity in non-RCC tumor types.. Journal of Clinical Oncology, 2015, 33, e13550-e13550.	1.6	0
205	The ORCHESTRA trial: A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in (mCRC) multi-organ metastatic colorectal cancer.. Journal of Clinical Oncology, 2015, 33, TPS3631-TPS3631.	1.6	0
206	Abstract 1820: Phosphoproteomics of a panel of AML cell lines reveals oncogenic signaling and candidate drivers. , 2015, , .		0
207	Abstract 3991: Standardization and optimization of circulating microRNA serum profiling in patients with cancer. , 2015, , .		0
208	Abstract 2007: Phosphoproteomics scaled-down to tumor biopsies for future TKI treatment selection. , 2015, , .		0
209	Optimal Human Blood Sampling for Platelet Research. Current Angiogenesis, 2014, 2, 157-161.	0.1	5
210	Mass Spectrometry-Based Proteomics: From Cancer Biology to Protein Biomarkers, Drug Targets, and Clinical Applications. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e504-e510.	3.8	37
211	Vî³9Vî´2-T cells as antigen presenting cells for iNKT cell based cancer immunotherapy. OncoImmunology, 2014, 3, e955343.	4.6	1
212	Genomic landscape of metastatic colorectal cancer. Nature Communications, 2014, 5, 5457.	12.8	61
213	CD1d-Restricted Antigen Presentation by Vî³9Vî´2-T Cells Requires Trogocytosis. Cancer Immunology Research, 2014, 2, 732-740.	3.4	19
214	Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms. Drug Resistance Updates, 2014, 17, 77-88.	14.4	56
215	Lymph Node Retrieval During Esophagectomy With and Without Neoadjuvant Chemoradiotherapy. Annals of Surgery, 2014, 260, 786-793.	4.2	134
216	Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review. Annals of Oncology, 2014, 25, 1914-1918.	1.2	65

#	Article	IF	Citations
217	High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. Cellular Oncology (Dordrecht), 2014, 37, 41-52.	4.4	12
218	A Novel Splice Site Mutation in the Noncoding Region ofBRCA2: Implications for Fanconi Anemia and Familial Breast Cancer Diagnostics. Human Mutation, 2014, 35, 442-446.	2.5	8
219	Mass Spectrometry-Based Serum and Plasma Peptidome Profiling for Prediction of Treatment Outcome in Patients With Solid Malignancies. Oncologist, 2014, 19, 1028-1039.	3.7	21
220	Bispecific antibody platforms for cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2014, 92, 153-165.	4.4	78
221	Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. BMC Palliative Care, 2014, 13, 42.	1.8	13
222	ShrinkBayes: a versatile R-package for analysis of count-based sequencing data in complex study designs. BMC Bioinformatics, 2014, 15, 116.	2.6	37
223	Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer. Journal of Extracellular Vesicles, 2014, 3, 25657.	12.2	29
224	Abstract 2989: High-dose, intermittent sunitinib as an alternative treatment strategy. , 2014, , .		3
225	Abstract CT216: Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma. Cancer Research, 2014, 74, CT216-CT216.	0.9	19
226	ImmunoPET imaging with 89Zr-cetuximab in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 11102-11102.	1.6	2
227	A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).. Journal of Clinical Oncology, 2014, 32, 2529-2529.	1.6	5
228	Effect of food on the pharmacokinetics (PK) of olaparib after oral dosing of the capsule formulation.. Journal of Clinical Oncology, 2014, 32, 2599-2599.	1.6	1
229	Identification of patients at risk for delirium on a medical oncology hospital ward.. Journal of Clinical Oncology, 2014, 32, 130-130.	1.6	1
230	Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience, 2014, 1, 844-853.	2.2	26
231	Phase I study of dalteparin in combination with sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, e15607-e15607.	1.6	0
232	Mass spectrometry-based serum and plasma peptide profiling for prediction of treatment outcome in patients with cancer.. Journal of Clinical Oncology, 2014, 32, e22221-e22221.	1.6	0
233	Abstract 908: Development of a cell proliferation assay to be used as a read-out system for determining thein vivopotency of bevacizumab in neutralizing the biological activity of VEGF in cancer patients. , 2014, , .		0
234	Proteomics in colorectal cancer translational research: Biomarker discovery for clinical applications. Clinical Biochemistry, 2013, 46, 466-479.	1.9	80

#	Article	IF	Citations
235	Analysis of the Novel Fanconi Anemia GeneSLX4/FANCPin Familial Breast Cancer Cases. Human Mutation, 2013, 34, 70-73.	2.5	21
236	Novel strategies towards the use of anti-angiogenic agents in breast cancer. European Journal of Pharmacology, 2013, 717, 36-39.	3.5	5
237	Aiming for a Better Understanding and Management of Cancer-Related Fatigue. Oncologist, 2013, 18, 1135-1143.	3.7	58
238	Successful Treatment of Renal Cell Carcinoma With Sorafenib After Effective but Hepatotoxic Sunitinib Exposure. Journal of Clinical Oncology, 2013, 31, e83-e86.	1.6	13
239	Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Epigenetics, 2013, 8, 907-920.	2.7	32
240	The future of colorectal cancer: implications of screening. Gut, 2013, 62, 1387-1389.	12.1	6
241	Tumor, skin, and plasma concentrations of protein kinase inhibitors (PKIs) in patients with advanced cancer.. Journal of Clinical Oncology, 2013, 31, 11087-11087.	1.6	2
242	Abstract 5641: Sunitinib inhibits AXL phosphorylation in tumor cells.. , 2013, , .		0
243	Abstract 4425: Characterisation of cellular transport and accumulation of six clinically approved tyrosine kinase inhibitors (TKIs) in colon cancer cells.. , 2013, , .		0
244	Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3552-3552.	1.6	0
245	Genome-wide methylation profiling to identify potential epigenetic biomarkers associated with response to sunitinib in metastatic renal cell cancer (mRCC) patients (pts).. Journal of Clinical Oncology, 2013, 31, 4566-4566.	1.6	1
246	Research Highlights. Immunotherapy, 2012, 4, 19-21.	2.0	1
247	Losses of Chromosome 5q and 14q Are Associated with Favorable Clinical Outcome of Patients with Gastric Cancer. Oncologist, 2012, 17, 653-662.	3.7	27
248	Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up. Journal of Clinical Oncology, 2012, 30, 567-570.	1.6	52
249	Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma. Oncology Letters, 2012, 3, 1293-1296.	1.8	19
250	Weight Loss of 5% or More Predicts Loss of Fat-Free Mass During Palliative Chemotherapy in Patients With Advanced Cancer: A Pilot Study. Nutrition and Cancer, 2012, 64, 826-832.	2.0	29
251	Activated iNKT cells promote VÎ³9VÎ´2-T cell anti-tumor effector functions through the production of TNF-Î±. Clinical Immunology, 2012, 142, 194-200.	3.2	16
252	Abstract 176: Kinase activity of tumor-derived exosomes as a potential biomarker for response to treatment. , 2012, , .		1

#	Article	IF	Citations
253	Targeting JNK-interacting protein 1 (JIP1) sensitises osteosarcoma to doxorubicin. Oncotarget, 2012, 3, 1169-1181.	1.8	36
254	Abstract 3533: Acquisition of antigen presenting cell functions by VÎ³9VÎ±2-T cells requires trogocytosis. , 2012, , .		0
255	Abstract 3608: Measurement of kinase activity in cancer cell lines and tumor tissue using a tyrosine kinase peptide substrate array. , 2012, , .		0
256	Abstract 1374: Cross-resistance and sensitivity of sunitinib resistant tumor cells. , 2012, , .		0
257	Response prediction by MALDI-TOF-MS serum peptide profiling of combination treatment with sorafenib and erlotinib in patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, e18094-e18094.	1.6	0
258	Bulldozing Î²-linked glycolipids for recognition by invariant NKT cells. Immunotherapy, 2012, 4, 20.	2.0	0
259	An Î±-galactosylceramide nose job shapes up iNKT cells. Immunotherapy, 2012, 4, 20-1.	2.0	0
260	Surgery of the primary in stage IV colorectal cancer with unresectable metastases. European Journal of Cancer, 2011, 47, S61-S66.	2.8	37
261	Clinical experience with Î±-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clinical Immunology, 2011, 140, 130-141.	3.2	87
262	Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. Medical Oncology, 2011, 28, 1136-1139.	2.5	5
263	Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis, 2011, 14, 135-141.	7.2	62
264	Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance. Clinical Cancer Research, 2011, 17, 7337-7346.	7.0	275
265	Abstract 5115: Comparative proteomics of exosomes secreted by a panel of cancer cell lines. , 2011, , .		0
266	Abstract 2852: Lysosomal sequestration of sunitinib may play a role in its resistance. , 2011, , .		0
267	Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. Analytical and Bioanalytical Chemistry, 2010, 397, 3163-3171.	3.7	29
268	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. Angiogenesis, 2010, 13, 1-14.	7.2	408
269	Signalling pathways in vasculogenic mimicry. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 18-28.	7.4	135
270	Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2010, 16, 2187-2197.	7.0	11

#	Article	IF	Citations
271	The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer. Clinical Cancer Research, 2010, 16, 1613-1623.	7.0	193
272	Subnuclear Proteomics in Colorectal Cancer. Molecular and Cellular Proteomics, 2010, 9, 988-1005.	3.8	61
273	The Relationship of Vascular Endothelial Growth Factor and Coagulation Factor (Fibrin and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	5.0	35
274	Abstract 4627: Proximal fluid proteome profiling of human colorectal cancer tissue reveals candidate biomarkers for CRC screening. , 2010, , .		0
275	Case 19-2009: Carcinoma of the Gastroesophageal Junction. New England Journal of Medicine, 2009, 361, 1315-1316.	27.0	0
276	Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis, 2009, 12, 69-79.	7.2	58
277	Proteomics of the TRAP-induced platelet releasate. Journal of Proteomics, 2009, 72, 91-109.	2.4	108
278	Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resistance Updates, 2009, 12, 114-126.	14.4	196
279	Combination Strategy Targeting the Hypoxia Inducible Factor-1Î± with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. Clinical Cancer Research, 2008, 14, 3589-3597.	7.0	105
280	A Multiple-Loop, Double-Cube Microarray Design Applied to Prostate Cancer Cell Lines with Variable Sensitivity to Histone Deacetylase Inhibitors. Clinical Cancer Research, 2008, 14, 6886-6894.	7.0	11
281	Platelets Take Up the Monoclonal Antibody Bevacizumab. Clinical Cancer Research, 2007, 13, 5341-5347.	7.0	105
282	Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model. Clinical Cancer Research, 2007, 13, 4201-4208.	7.0	111
283	Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 4538-4546.	7.0	82
284	Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer, 2007, 7, 475-485.	28.4	468
285	Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemotherapy and Pharmacology, 2007, 60, 329-339.	2.3	21
286	Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1Î±. Cancer Research, 2006, 66, 8814-8821.	0.9	292
287	Inhibition of angiogenesis in cancer patients. Expert Opinion on Emerging Drugs, 2005, 10, 403-412.	2.4	19
288	Angiogenesis inhibitors: What is the clinical future?. , 2005, 63, 67-91.		1

#	Article	IF	Citations
289	Circulating endothelial cells in cancer patients do not express tissue factor. Cancer Letters, 2004, 213, 241-248.	7.2	23
290	Vascular Endothelial Growth Factor-165 Overexpression Stimulates Angiogenesis and Induces Cyst Formation and Macrophage Infiltration in Human Ovarian Cancer Xenografts. American Journal of Pathology, 2002, 160, 537-548.	3.8	80
291	Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clinical Cancer Research, 2002, 8, 3747-54.	7.0	61
292	Vascular endothelial growth factorâ€“stimulated endothelial cells promote adhesion and activation of platelets. Blood, 2000, 96, 4216-4221.	1.4	187
293	The Role of Vascular Endothelial Growth Factor (VEGF) in Tumor Angiogenesis and Early Clinical Development of VEGFReceptor Kinase Inhibitors. Clinical Breast Cancer, 2000, 1, S80-S84.	2.4	77
294	Treatment of the Kasabach-Merritt Syndrome with Pegylated Recombinant Human Megakaryocyte Growth and Development Factor in Mice: Elevated Platelet Counts, Prolonged Survival, and Tumor Growth Inhibition. Pediatric Research, 1999, 46, 562-562.	2.3	20
295	Effects of Chemotherapy on Pathologic and Biologic Characteristics of Locally Advanced Breast Cancer. American Journal of Clinical Pathology, 1997, 107, 211-218.	0.7	104